XML 57 R41.htm IDEA: XBRL DOCUMENT v3.20.4
Significant Accounting Policies (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 12 Months Ended 13 Months Ended
Nov. 29, 2020
Dec. 31, 2020
Dec. 31, 2019
Jan. 31, 2021
Jul. 08, 2020
Jan. 31, 2020
Jan. 02, 2019
Significant Accounting Policies (Textual)              
Operating lease right of use assets and operating lease liabilities             $ 42
Operating lease right of use assets   $ 22 $ 22        
Percentage of deposits   8.33%          
Severance expense   $ 16 $ 17        
Income tax benefit, description   The tax benefit as the largest amount that is more than 50% (cumulative basis) likely to be realized upon ultimate settlement.          
Amortization of right use assets and operating lease liabilities   $ 20          
Aggregate purchase           7,500  
Purchase price per share           $ 1  
Least percentage of carrying amount   10.00%          
Percentage of debt   10.00%          
Percentage of contingent obligation   37.00%          
Description of contingent obligation   Including, among others, the dry eye US market size in 2025 (USD 2.9 Billion), the maximum penetration rate of the product into the U.S. market - 12%, the patent expiration date (2038), the operational profit rate - 26%, the probabilities for FDA phases approvals, and the risk-adjusted rate for discounting future cash flows - 20.3%.          
Bonus agreements percentage   80.00%          
Cash dividends received, percentage   80.00%          
Description of bonus agreements (i) the Company will waive the requirement that Bonus will effect the Nasdaq Listing and, in relation thereto, conduct the Milestone Closing (as defined in the Bonus Agreements), which means that, at the Closing, $3.7 million will be released from an existing escrow account to Bonus, whereas the 28,413,000 Bonus Shares held in such escrow (the "Nasdaq Milestone Shares") will be released to the Company (20% of the shares) and to the Company's former holders of Series B Preferred Stock (the "Former Series B Holders"); (ii) the Company will waive approximately $120in liquidated damages that accrued as a result of the delay in effecting the Nasdaq Listing; and (iii) Bonus agreed to extend the period for the Company to create, and cause its Israeli subsidiaries to create, certain first priority liens in favor of Bonus to secure the Company's obligations under the Bonus Exchange Agreement, including certain related negative covenants. The Closing was subject to customary conditions, including obtaining the approval of the TASE, and occurred on December 30, 2020. It should be noted that, in accordance with the Securities Purchase Agreement, dated January 9, 2020 (as amended), by and among the Company and the Former Series B Holders, the Company was required to transfer 80% of the Milestone Settlement Shares and 80% of the Nasdaq Milestone Shares to such investors.            
Gross proceeds       $ 7,500      
Minimum [Member]              
Significant Accounting Policies (Textual)              
Present value of debt instrument percentage   10.00%          
Series B Preferred Stock [Member]              
Significant Accounting Policies (Textual)              
Number of bonus shares distributed by company         68,191,200    
Redeem Series B Preferred Stock, description (i) the Milestone Settlement Shares, which, as defined in the Addendum, means Bonus Shares equal to the quotient obtained by dividing US$500 expressed in NIS (based on the exchange rate set in the Addendum) by NIS 0.50, and (ii) the HCW Settlement Shares (together with the Milestone Settlement Shares, the “Settlement Shares”), which, as defined in the Addendum, means Bonus Shares equal to the quotient obtained by dividing US$350 expressed in NIS (based on the exchange rate set in the Addendum) by NIS 0.50.